In my opinion, the CHM meeting is very crucial, and now there's a 50% chance that the MHRA will approve DCVAX-L. This gives us strong confidence to buy at these levels, regardless of when the approval happens. Investing in biotech stocks is always a gamble, and until approval is granted, there's no guarantee of the return on our investment. However, after seeing this news, we can approach buying the stock with more confidence at these price levels.
"the Medicines and Healthcare products Regulatory Agency (MHRA) follows the recommendations and outcomes of the Commission on Human Medicines (CHM) meetings. The CHM is an expert advisory body that provides independent advice to the MHRA on matters related to the safety, quality, and efficacy of medicines, vaccines, and medical devices.
The MHRA takes into account the advice and recommendations provided by the CHM when making regulatory decisions. However, the MHRA has the final authority in its decision-making process, which may sometimes involve taking additional factors into consideration beyond the CHM's guidance.
In short, while the CHM plays a key advisory role, the MHRA ultimately makes the decisions based on the committee's input and other regulatory criteria."
Bullish
Market Data 
Markets 
AI
